title: Delafloxacin for the treatment of respiratory and skin infections.
abstract: BACKGROUND
  There has been a striking increase in the emergence of multidrug-resistant pathogens in recent times. Delafloxacin is a novel, broad-spectrum fluoroquinolone with antimicrobial activity against resistant Gram-positive, Gram-negative and anaerobic organisms. It has the potential to treat a variety of infections including complicated skin and skin structure infections and respiratory tract infections.
  
  
  METHODS
  In this review, the authors report the microbiological spectrum of activity of delafloxacin as well as its pharmacokinetic characteristics. They also report the results of recent studies investigating its safety and efficacy.
  
  
  CONCLUSIONS
  The profile of delafloxacin offers several advantages. Delafloxacin presents a broad spectrum of activity against pathogens involved in respiratory infections and complicated skin and skin structure infections (SSSIs), including methicillin-resistant Staphylococcus aureus. It has also shown activity against Gram-negative pathogens, such as quinolone-susceptible and -resistant strains of Escherichia coli and Klebsiella pneumoniae and quinolone-susceptible Pseudomonas aeruginosa. The availability of an oral formulation supports its use in sequential therapy. The efficacy and tolerability of delafloxacin have been demonstrated in Phase II clinical trials in comparison with moxifloxacin for respiratory infections and linezolid and vancomycin in SSSIs. Compared with other quinolones such as moxifloxacin, delafloxacin showed comparable efficacy and a lower rate of adverse effects. The results of new Phase III studies are awaited to confirm delafloxacin's future applications in the treatment of SSSIs.
authors.affiliation: Santa Maria Misericordia University Hospital, Infectious Diseases Division , Piazzale S. Maria della Misericordia, n. 15, 33100, Udine , Italy + 86 21 38804518; extn. 8319 ; + 39 0432 559360 ; mattba@tin.it.
authors.forename: Matteo
authors.initials: M
authors.lastname: Bassetti
authors.forename: Paola
authors.initials: P
authors.lastname: Della Siega
authors.forename: Davide
authors.initials: D
authors.lastname: Pecori
authors.forename: Claudio
authors.initials: C
authors.lastname: Scarparo
authors.forename: Elda
authors.initials: E
authors.lastname: Righi
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001421:Bacteria, Anaerobic / Q000187:drug effects; D024901:Drug Resistance, Multiple, Bacterial; D024841:Fluoroquinolones / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D006090:Gram-Negative Bacteria / Q000187:drug effects; D006094:Gram-Positive Bacteria / Q000187:drug effects; D006801:Humans; D012141:Respiratory Tract Infections / Q000188:drug therapy / Q000382:microbiology; D017192:Skin Diseases, Bacterial / Q000188:drug therapy / Q000382:microbiology
chemical_list: D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; C477891:delafloxacin
keywords: delafloxacin; fluoroquinolones; methicillin-resistant Staphylococcus aureus; respiratory infections